Organization Profile

You just read:

Transition Therapeutics Announces Enrollment of the First Patient in Phase 2 Study of ELND005 (Scyllo-inositol) for the Treatment of Agitation/Aggression in Patients with Alzheimer's Disease

News provided by

Transition Therapeutics Inc.

Nov 28, 2012, 08:30 ET